Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlova, Kristina V., Yanus, Grigory A., Aleksakhina, Svetlana N., Venina, Aigul R., Iyevleva, Aglaya G., Demidov, Lev V., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477486/
https://www.ncbi.nlm.nih.gov/pubmed/31043947
http://dx.doi.org/10.1159/000495782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477486/
https://www.ncbi.nlm.nih.gov/pubmed/31043947
http://dx.doi.org/10.1159/000495782

Ejemplares similares